D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Timing of the Components of the HIV Life Cycle in Productively Infected CD4+ T Cells in a Population of HIV-Infected Individuals
TL;DR: It is found that HIV requires an average of 52 h between export of virions in one generation to export in the next, with most of this (33 h) taken up by reverse transcription.
Journal ArticleDOI
Sexual dysfunction in advanced HIV disease
TL;DR: The findings from an investigation of sexual dysfunction in a large group of homosexual men with severe HIV disease are described.
Journal ArticleDOI
Clinical update: adverse effects of antiretroviral therapy
TL;DR: The adverse effects of antiretroviral therapy (ART) cause substantial morbidity and compromise adherence which can lead to drug resistance, and treatment guidelines recommend against universal immediate ART partly because of toxicities (table).
Journal ArticleDOI
Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.
Philippe Vanhems,Jean Lambert,David A. Cooper,Luc Perrin,Andrew Carr,Bernard Hirschel,Jeanette Vizzard,Sabine Kinloch-de Loes,Robert Allard +8 more
TL;DR: The number of symptoms and signs at the time of acute HIV-1 illness affects disease progression and survival, even in symptomatic patients who have undergone seroconversion.
Journal ArticleDOI
Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells
Chantelle L Ahlenstiel,Heidi G. W. Lim,David A. Cooper,Takaomi Ishida,Anthony D. Kelleher,Kazuo Suzuki +5 more
TL;DR: Examination of subcellular co-localization of Ago proteins with promoter-targeted siRNAs during TGS of SIV and HIV-1 infection reveals a novel nuclear trafficking mechanism for RITS-like components involving the actin cytoskeleton and establishes a model for elucidating mammalian TGS.